Partnerships Picks For GeNeuro’s MS Antibody
GeNeuro’s CEO And His Mission To Bring Anti-HERV Benefits To MS Patients
Executive Summary
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.
You may also be interested in...
GeNeuro, Servier 'Disappointed' With Mid-Way Phase IIb Multiple Sclerosis Study
GeNeuro and partner Servier voiced disappointment over results seen midway through a Phase IIb trial studying a potential cause of multiple sclerosis - but insisted the trial will continue for the final 6 months.
Insmed CEO On Innovating To Compete In Rare Disease
Leading the company with the only therapy approved for NTM lung disease, Will Lewis tells In Vivo that success comes from giving researchers room to breath, visualizing patient benefit, and sailing into uncharted waters.
Spotting Zebras: Technology Cutting Through The Diagnostic Odyssey
In Vivo talked to two organizations making progress in the diagnosis of rare diseases using software and genomic sequencing.